RELATIONSHIP BETWEEN VISFATIN AND SOME BIOMARKERS OF BONE TURNOVER IN PATIENTS WITH CHRONIC KIDNEY DISEASE
DOI:
https://doi.org/10.35120/medisij010331pKeywords:
chronic kidney disease, visfatin, endothelial dysfunction, inflammation, FGF-23Abstract
Chronic kidney disease (CKD) is a progressive disease that might result in an end stage renal disease (ESRD), raising cardiovascular morbidity and mortality. Life expectancy among patients with CKD could significantly be reduced as a result of an advanced atherosclerosis and followed by a premature death from cardiovascular disease (CVD). CVD is a condition of a subclinical systematic inflammation that involves cytokines produced by adipose tissue. Visfatin is an adipocytokine with potentially important effects on glucose metabolism and atherosclerosis. Therefore, it could be treated like a new marker of endothelial dysfunction (ED) in CKD patients. It has been suggested that visfatin levels could increase as CKD progresses, which could be due to either the chronic inflammation associated with CKD and/or the hypoxia resulting from tubular necrosis, anemia and reduced capillary blood flow. As CKD progresses, visfatin levels among these patients most often spell increased mortality caused by cardiovascular events.
The current research has been conducted among a total of 80 subjects with CKD who were divided into two groups - pre-dialysis (30) and hemodialysis treatment (50) patients from the Nephrology and Dialysis Clinic at the UMHAT "Sveta Marina" Varna. Demographics indicators and levels of visfatin, iFGF-23 and iPTH were inevstigated.
Downloads
References
Adamczak M, Chudek J, Wiecek A. (2009). Adiponectin in patients with chronic kidney disease. Semin Dial;22:391–395
Axelsson J, Stenvinkel P. (2008) Role of fat mass and adipokines in chronic kidney disease. Curr Opin Nephrol Hypertens; 17:25–31.
Axelsson J, Witasp A, Carrero JJ, et al. (2007). Circulating levels of visfatin/Pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD, Am J Kidney Dis, vol. 49 (pg. 237- 244)
Benkova - Petrova M. (2021). Relationship between erythropoietin resistance and secondary hyperparathyroidism in dialysis patients. Dissertation, MU – Varna.
Benkova-Petrova M., Petrov A., Staykova, S. (2020). Erythropoietin resistance in patients undergoing dialysis. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS),Vol.19, 3, 56-59
Block GA, Klassen PS, Lazarus JM, et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis, J Am Soc Nephrol, vol. 15 (pg. 2208-2218)
Erten M. (2021). Visfatin as a Promising Marker of Cardiometabolic Risk. Acta Cardiol Sin. 2021 Sep; 37(5):464-472. doi: 10.6515/ACS.202109_37(5).20210323B.PMID: 34584379
Fatima S, Sasivathanam N, Devi Nirmala K, Begum A, Vanitha K. (2007). Serum Visfatin – А Noval Marker of Chronic Kidney Disease, Journal of Medical Sciences and Health;Volume 3; Issue 1
Iglesias P, Diez JJ. (2010). Adipose tissue in renal disease: clinical significance and prognostic implications. Nephrol Dial Transplant; 25: 2066–2077.
Marthi A, Donovan K, Haynes R, Wheeler DC, Baigent C, Rooney CM, et al (2009). Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J Am Soc Nephrol; 29:2015–27. doi: 10.1681/ASN.2017121334
Mirza MA, Larsson A, Lind L, et al. (2009). Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community, Atherosclerosis, vol. 205 (pg. 385-390)
Mirza Mai, Alsiö J, Hammarstedt A, Erben RG, Michaëlsson K, Tivesten A, et al. (2011). Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 31:219–27. doi: 10.1161/ATVBAHA.110.214619
Miyamoto S, Sharma K. (2013). Adipokines protecting CKD. Nephrol Dial Transplant; 28(suppl 4):iv15–iv22.
Nüsken KD, Petrasch M, Rauh M, et al. (2009). Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant; 24:2832–2838.
Petrov A. (2021). General health awareness and culture of persons with chronic kidney diseases and their influence on the healing process; Varna Medical Forum, item 10, 2021, issue 2
Revollo JR, Grimm AA, Imai S. (2007). The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol; 23:164–170.
Shankar A, Syamala S, Xiao J, Muntner P. (2012). Relationship between plasma leptin level and chronic kidney disease. Int J Nephrol; 2012:269532
Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, et al. (2008). Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol; 295:1485–1494
Spoto B, Pizzini P, Tripepi G, Mallamaci F, Zoccali C. (2018). Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. Nephrol Dial Transplant.33:1764–9. doi: 10.1093/ndt/gfx344
Stam F, van Guldener C, Becker A, Dekker JM, Heine RJ, Bouter LM, et al. (2006). Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol; 17: 537–45.
Stastny J, Bienertova-Vasku J, Vasku A. (2012). Visfatin and its role in obesity development. Diabetes Metab Syndr; 6:120–124
Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. (2010). Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res; 25:1711–23. doi: 10.1002/jbmr.65
Wolf M, Shah A, Gutierrez O, et al. (2007). Vitamin D levels and early mortality among incident hemodialysis patients, Kidney Int, vol. 72 (pg. 1004-1013)
Yilmaz M.I, Saglam M, Carrero J. J, Qureshi A.R, Caglar K, Eyileten T, Sonmez A, Cakir E, Yenicesu M, Lindholm B. (2008). Serum visfatin concentration and endothelial dysfunction in chronic kidney disease, Nephrology Dialysis Transplantation, Volume 23, Issue 3, Pages 959 -965, https://doi.org/10.1093/ndt/gfm727
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
